{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-ibd","title":"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThis keeps the discussion on one degeneration layer per compound without overlap.\n\n## What the evidence actually shows\n\nHuman data on Tesamorelin itself comes from HIV lipodystrophy trials (preclinical|mechanistic|speculative tiers do not apply here). Multiple randomized placebo-controlled trials showed visceral adipose tissue reduction and lipid improvements after 26 weeks of daily 2 mg subcutaneous tesamorelin. One trial also measured modest liver fat reduction. No human trial has tested Tesamorelin in IBD patients (human tier: none).\n\nSeparate human evidence exists for recombinant GH in Crohn's disease. One double-blind placebo-controlled study in 37 patients with moderate-to-severe active Crohn's gave GH for 4 months and reported greater CDAI reduction versus placebo (human tier). Preclinical work in DSS colitis mouse models showed GH overexpression improved inflammation resolution and mucosal repair (preclinical tier).\n\nTesamorelin's effect on GH/IGF-1 is documented in HIV cohorts but never linked directly to IBD outcomes in controlled human studies (human tier: absent for this condition).\n\n## What scientists say\n\nGrowth factor reviews note GH and IGF-1 relevance to IBD via effects on epithelial cells, mesenchymal cells, and immune balance. IL-6 may blunt IGF-1 response in Crohn's. Scientists emphasize these are mechanistic observations, not treatment recommendations. No publications position Tesamorelin as an IBD agent.\n\n## What people say on Reddit\n\nReddit threads mention Tesamorelin in speculative IBD stacks alongside other peptides for metabolic or reparative support. One post describes a hypothetical mouse study combining multiple compounds including Tesamorelin for DSS colitis reversal (anecdotal tier). User reports of personal Tesamorelin use in Crohn's remain absent or limited to general fat-loss comments unrelated to gut symptoms (anecdotal tier: sparse, indirect).\n\n## What people say on X\n\nPosts referencing Tesamorelin and IBD or gut conditions are essentially nonexistent. One unrelated post lists Tesamorelin among peptides in a gut-health context without outcome details (anecdotal tier: negligible).\n\n## What we do not know\n\nNo human trials exist for Tesamorelin in IBD. Effects on intestinal barrier, cytokine profiles, or remission rates remain untested. Duration, dosing relevance, and long-term gut-specific outcomes are unknown. Translation from HIV visceral-fat data or GH Crohn's data to this setting stays speculative.\n\n## Safety and limits\n\nTesamorelin carries documented side effects from HIV trials including injection-site reactions, joint pain, and possible glucose changes. Any use outside approved indications lacks safety data in IBD populations. Evidence grading here separates clearly: strong human data for visceral fat reduction, zero human data for IBD, mechanistic overlap via GH axis only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Establishes the compound's documented human effect on the GH/visceral fat layer referenced for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials have tested Tesamorelin in IBD patients.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the complete absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides the only human IBD data on the GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH overexpression improved mucosal repair in DSS colitis mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Shows the mechanistic repair layer in animal gut inflammation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents the anecdotal layer without overstating user experience.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20554713/","title":"Effects of tesamorelin in HIV patients with excess abdominal fat","quote":"Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk","summary":"Pooled phase 3 analysis showing visceral fat reduction.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"aac2ffeddacfc751bb772a292d6c8a344179fd0fe42c3a823bd86ded3f57e28b"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV","quote":"Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV","summary":"Confirms approved human use for visceral fat.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"verified","prev":"aac2ffeddacfc751bb772a292d6c8a344179fd0fe42c3a823bd86ded3f57e28b","hash":"a3635a61191a8c2a43cddbc9a7caf8510ee68836193acaf9138f58adb83010af"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2841424/","title":"Growth Factors as Treatment for Inflammatory Bowel Disease","quote":"A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease showed that therapy with recombinant GH may be a beneficial treatment.","summary":"Reviews GH/IGF-1 in IBD plus the human Crohn's GH trial and mouse data.","claim_ids":["c3","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"unverified","prev":"a3635a61191a8c2a43cddbc9a7caf8510ee68836193acaf9138f58adb83010af","hash":"e504511778e61ddf6622005ea11d10874da320c77b90766fff9ab4aa147f5d12"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/","title":"Peptide Research for Crohn's Disease","quote":"Tesamorelin elevates GH/IGF-1 for metabolic and reparative support.","summary":"Speculative stack mention in hypothetical IBD context.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"unverified","prev":"e504511778e61ddf6622005ea11d10874da320c77b90766fff9ab4aa147f5d12","hash":"1da3e168618bd1b14baa924af75b66c637233671c6ad08a2a9338a906f626c92"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:20:09.161Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThis keeps the discussion on one degeneration layer per compound without overlap.\n\n## What the evidence actually shows\n\nHuman data on Tesamorelin itself comes from HIV lipodystrophy trials (preclinical|mechanistic|speculative tiers do not apply here). Multiple randomized placebo-controlled trials showed visceral adipose tissue reduction and lipid improvements after 26 weeks of daily 2 mg subcutaneous tesamorelin. One trial also measured modest liver fat reduction. No human trial has tested Tesamorelin in IBD patients (human tier: none).\n\nSeparate human evidence exists for recombinant GH in Crohn's disease. One double-blind placebo-controlled study in 37 patients with moderate-to-severe active Crohn's gave GH for 4 months and reported greater CDAI reduction versus placebo (human tier). Preclinical work in DSS colitis mouse models showed GH overexpression improved inflammation resolution and mucosal repair (preclinical tier).\n\nTesamorelin's effect on GH/IGF-1 is documented in HIV cohorts but never linked directly to IBD outcomes in controlled human studies (human tier: absent for this condition).\n\n## What scientists say\n\nGrowth factor reviews note GH and IGF-1 relevance to IBD via effects on epithelial cells, mesenchymal cells, and immune balance. IL-6 may blunt IGF-1 response in Crohn's. Scientists emphasize these are mechanistic observations, not treatment recommendations. No publications position Tesamorelin as an IBD agent.\n\n## What people say on Reddit\n\nReddit threads mention Tesamorelin in speculative IBD stacks alongside other peptides for metabolic or reparative support. One post describes a hypothetical mouse study combining multiple compounds including Tesamorelin for DSS colitis reversal (anecdotal tier). User reports of personal Tesamorelin use in Crohn's remain absent or limited to general fat-loss comments unrelated to gut symptoms (anecdotal tier: sparse, indirect).\n\n## What people say on X\n\nPosts referencing Tesamorelin and IBD or gut conditions are essentially nonexistent. One unrelated post lists Tesamorelin among peptides in a gut-health context without outcome details (anecdotal tier: negligible).\n\n## What we do not know\n\nNo human trials exist for Tesamorelin in IBD. Effects on intestinal barrier, cytokine profiles, or remission rates remain untested. Duration, dosing relevance, and long-term gut-specific outcomes are unknown. Translation from HIV visceral-fat data or GH Crohn's data to this setting stays speculative.\n\n## Safety and limits\n\nTesamorelin carries documented side effects from HIV trials including injection-site reactions, joint pain, and possible glucose changes. Any use outside approved indications lacks safety data in IBD populations. Evidence grading here separates clearly: strong human data for visceral fat reduction, zero human data for IBD, mechanistic overlap via GH axis only.","claims":[{"id":"c1","text":"Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Establishes the compound's documented human effect on the GH/visceral fat layer referenced for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials have tested Tesamorelin in IBD patients.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the complete absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides the only human IBD data on the GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH overexpression improved mucosal repair in DSS colitis mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Shows the mechanistic repair layer in animal gut inflammation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents the anecdotal layer without overstating user experience.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20554713/","title":"Effects of tesamorelin in HIV patients with excess abdominal fat","quote":"Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV","quote":"Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2841424/","title":"Growth Factors as Treatment for Inflammatory Bowel Disease","quote":"A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease showed that therapy with recombinant GH may be a beneficial treatment.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/","title":"Peptide Research for Crohn's Disease","quote":"Tesamorelin elevates GH/IGF-1 for metabolic and reparative support.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":22871,"tokens_out":2681,"cost":0.03529125,"prev_hash":"genesis","hash":"039e581891576db3b1a168ecaeada741a244b88b4acdb97e129449ac1e47f3f1"}],"provenance":[{"ts":"2026-06-29T23:20:09.161Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Ibd\nSlug: tesamorelin-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn'","response":"{\n  \"slug\": \"tesamorelin-ibd\",\n  \"title\": \"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\\n\\nThis keeps the discussion on one degeneration layer per compound without overlap.\\n\\n## What the evidence actually shows\\n\\nHuman data on Tesamorelin its","tokens_in":22871,"tokens_out":2681,"cost":0,"prev":"genesis","hash":"a997429b28f93ef7d438c75e71e38a2c0c8779b9a3db68f73a5e17f05bfecdef"},{"ts":"2026-07-17T02:42:23.490Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-ibd","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a997429b28f93ef7d438c75e71e38a2c0c8779b9a3db68f73a5e17f05bfecdef","hash":"5ef59e84c673591e84f3b997a4453ca57fe6a5fca4a24ca13aed6719fee05f59"}],"energy":{"passes":2,"tokens_in":22871,"tokens_out":2681,"tokens_total":25552,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5ef59e84c673591e84f3b997a4453ca57fe6a5fca4a24ca13aed6719fee05f59"},"posted_at":"2026-06-29T21:33:33.230Z","created_at":"2026-06-29T21:33:33.230Z","updated_at":"2026-07-17T02:42:23.490Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-ibd","json":"https://miscsubjects.com/api/articles/tesamorelin-ibd","bundle":"https://miscsubjects.com/api/articles/tesamorelin-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-ibd","json":"/api/articles/tesamorelin-ibd","markdown":"/api/articles/tesamorelin-ibd/bundle?format=markdown","skill":"/api/articles/tesamorelin-ibd/skill","topology":"/api/articles/tesamorelin-ibd/topology","versions":"/api/articles/tesamorelin-ibd/revisions","invocations":"/api/articles/tesamorelin-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"134ca73b860735312bd49b0d645eaf0de71dad8f6af3614ac49f245bc1eeb06e","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-ibd","slug":"tesamorelin-ibd","title":"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-ibd","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-ibd/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-ibd\ndescription: Apply the Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-ibd). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-ibd.\n- Read claims and relationships at /api/articles/tesamorelin-ibd/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down if you have IBD Crohn's / colitis IBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, \n\n## Representations\n\n- Human: /a/tesamorelin-ibd\n- JSON: /api/articles/tesamorelin-ibd\n- Relationships: /api/articles/tesamorelin-ibd/topology\n- History: /api/articles/tesamorelin-ibd/revisions\n"},"json":{"route":"/api/articles/tesamorelin-ibd","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-ibd/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","ibd"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-ibd/invocations?status=success","failure_events":"/api/articles/tesamorelin-ibd/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-ibd","title":"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThis keeps the discussion on one degeneration layer per compound without overlap.\n\n## What the evidence actually shows\n\nHuman data on Tesamorelin itself comes from HIV lipodystrophy trials (preclinical|mechanistic|speculative tiers do not apply here). Multiple randomized placebo-controlled trials showed visceral adipose tissue reduction and lipid improvements after 26 weeks of daily 2 mg subcutaneous tesamorelin. One trial also measured modest liver fat reduction. No human trial has tested Tesamorelin in IBD patients (human tier: none).\n\nSeparate human evidence exists for recombinant GH in Crohn's disease. One double-blind placebo-controlled study in 37 patients with moderate-to-severe active Crohn's gave GH for 4 months and reported greater CDAI reduction versus placebo (human tier). Preclinical work in DSS colitis mouse models showed GH overexpression improved inflammation resolution and mucosal repair (preclinical tier).\n\nTesamorelin's effect on GH/IGF-1 is documented in HIV cohorts but never linked directly to IBD outcomes in controlled human studies (human tier: absent for this condition).\n\n## What scientists say\n\nGrowth factor reviews note GH and IGF-1 relevance to IBD via effects on epithelial cells, mesenchymal cells, and immune balance. IL-6 may blunt IGF-1 response in Crohn's. Scientists emphasize these are mechanistic observations, not treatment recommendations. No publications position Tesamorelin as an IBD agent.\n\n## What people say on Reddit\n\nReddit threads mention Tesamorelin in speculative IBD stacks alongside other peptides for metabolic or reparative support. One post describes a hypothetical mouse study combining multiple compounds including Tesamorelin for DSS colitis reversal (anecdotal tier). User reports of personal Tesamorelin use in Crohn's remain absent or limited to general fat-loss comments unrelated to gut symptoms (anecdotal tier: sparse, indirect).\n\n## What people say on X\n\nPosts referencing Tesamorelin and IBD or gut conditions are essentially nonexistent. One unrelated post lists Tesamorelin among peptides in a gut-health context without outcome details (anecdotal tier: negligible).\n\n## What we do not know\n\nNo human trials exist for Tesamorelin in IBD. Effects on intestinal barrier, cytokine profiles, or remission rates remain untested. Duration, dosing relevance, and long-term gut-specific outcomes are unknown. Translation from HIV visceral-fat data or GH Crohn's data to this setting stays speculative.\n\n## Safety and limits\n\nTesamorelin carries documented side effects from HIV trials including injection-site reactions, joint pain, and possible glucose changes. Any use outside approved indications lacks safety data in IBD populations. Evidence grading here separates clearly: strong human data for visceral fat reduction, zero human data for IBD, mechanistic overlap via GH axis only.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-ibd/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Establishes the compound's documented human effect on the GH/visceral fat layer referenced for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials have tested Tesamorelin in IBD patients.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the complete absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides the only human IBD data on the GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH overexpression improved mucosal repair in DSS colitis mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Shows the mechanistic repair layer in animal gut inflammation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents the anecdotal layer without overstating user experience.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20554713/","title":"Effects of tesamorelin in HIV patients with excess abdominal fat","quote":"Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk","summary":"Pooled phase 3 analysis showing visceral fat reduction.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"aac2ffeddacfc751bb772a292d6c8a344179fd0fe42c3a823bd86ded3f57e28b"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV","quote":"Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV","summary":"Confirms approved human use for visceral fat.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"verified","prev":"aac2ffeddacfc751bb772a292d6c8a344179fd0fe42c3a823bd86ded3f57e28b","hash":"a3635a61191a8c2a43cddbc9a7caf8510ee68836193acaf9138f58adb83010af"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2841424/","title":"Growth Factors as Treatment for Inflammatory Bowel Disease","quote":"A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease showed that therapy with recombinant GH may be a beneficial treatment.","summary":"Reviews GH/IGF-1 in IBD plus the human Crohn's GH trial and mouse data.","claim_ids":["c3","c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"unverified","prev":"a3635a61191a8c2a43cddbc9a7caf8510ee68836193acaf9138f58adb83010af","hash":"e504511778e61ddf6622005ea11d10874da320c77b90766fff9ab4aa147f5d12"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/","title":"Peptide Research for Crohn's Disease","quote":"Tesamorelin elevates GH/IGF-1 for metabolic and reparative support.","summary":"Speculative stack mention in hypothetical IBD context.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:20:08.486Z","link_status":"ok","quote_status":"unverified","prev":"e504511778e61ddf6622005ea11d10874da320c77b90766fff9ab4aa147f5d12","hash":"1da3e168618bd1b14baa924af75b66c637233671c6ad08a2a9338a906f626c92"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:20:09.161Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis","register":"source_ledger","body":"## What's breaking down if you have IBD (Crohn's / colitis)\n\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **Tesamorelin** → GH axis / visceral fat\n\nThis keeps the discussion on one degeneration layer per compound without overlap.\n\n## What the evidence actually shows\n\nHuman data on Tesamorelin itself comes from HIV lipodystrophy trials (preclinical|mechanistic|speculative tiers do not apply here). Multiple randomized placebo-controlled trials showed visceral adipose tissue reduction and lipid improvements after 26 weeks of daily 2 mg subcutaneous tesamorelin. One trial also measured modest liver fat reduction. No human trial has tested Tesamorelin in IBD patients (human tier: none).\n\nSeparate human evidence exists for recombinant GH in Crohn's disease. One double-blind placebo-controlled study in 37 patients with moderate-to-severe active Crohn's gave GH for 4 months and reported greater CDAI reduction versus placebo (human tier). Preclinical work in DSS colitis mouse models showed GH overexpression improved inflammation resolution and mucosal repair (preclinical tier).\n\nTesamorelin's effect on GH/IGF-1 is documented in HIV cohorts but never linked directly to IBD outcomes in controlled human studies (human tier: absent for this condition).\n\n## What scientists say\n\nGrowth factor reviews note GH and IGF-1 relevance to IBD via effects on epithelial cells, mesenchymal cells, and immune balance. IL-6 may blunt IGF-1 response in Crohn's. Scientists emphasize these are mechanistic observations, not treatment recommendations. No publications position Tesamorelin as an IBD agent.\n\n## What people say on Reddit\n\nReddit threads mention Tesamorelin in speculative IBD stacks alongside other peptides for metabolic or reparative support. One post describes a hypothetical mouse study combining multiple compounds including Tesamorelin for DSS colitis reversal (anecdotal tier). User reports of personal Tesamorelin use in Crohn's remain absent or limited to general fat-loss comments unrelated to gut symptoms (anecdotal tier: sparse, indirect).\n\n## What people say on X\n\nPosts referencing Tesamorelin and IBD or gut conditions are essentially nonexistent. One unrelated post lists Tesamorelin among peptides in a gut-health context without outcome details (anecdotal tier: negligible).\n\n## What we do not know\n\nNo human trials exist for Tesamorelin in IBD. Effects on intestinal barrier, cytokine profiles, or remission rates remain untested. Duration, dosing relevance, and long-term gut-specific outcomes are unknown. Translation from HIV visceral-fat data or GH Crohn's data to this setting stays speculative.\n\n## Safety and limits\n\nTesamorelin carries documented side effects from HIV trials including injection-site reactions, joint pain, and possible glucose changes. Any use outside approved indications lacks safety data in IBD populations. Evidence grading here separates clearly: strong human data for visceral fat reduction, zero human data for IBD, mechanistic overlap via GH axis only.","claims":[{"id":"c1","text":"Tesamorelin reduces visceral adipose tissue in HIV patients per multiple RCTs.","section":"What the evidence actually shows","tier":"human","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Establishes the compound's documented human effect on the GH/visceral fat layer referenced for the reader.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No human trials have tested Tesamorelin in IBD patients.","section":"What we do not know","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies the complete absence of direct evidence for the condition.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Recombinant GH improved CDAI scores in a small double-blind Crohn's trial.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Provides the only human IBD data on the GH axis.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"GH overexpression improved mucosal repair in DSS colitis mouse models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3"],"source_status":"sourced","why_material":"Shows the mechanistic repair layer in animal gut inflammation.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"Reddit mentions of Tesamorelin in IBD contexts are limited to speculative stacks.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4"],"source_status":"sourced","why_material":"Documents the anecdotal layer without overstating user experience.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:20:08.800Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/20554713/","title":"Effects of tesamorelin in HIV patients with excess abdominal fat","quote":"Treatment with tesamorelin reduces VAT and maintains the reduction for up to 52 wk","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38905488/","title":"Efficacy and safety of tesamorelin in people with HIV","quote":"Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV","link_status":"ok","quote_status":"verified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2841424/","title":"Growth Factors as Treatment for Inflammatory Bowel Disease","quote":"A double-blind and placebo-controlled study in 37 patients with moderate-to-severe active Crohn's disease showed that therapy with recombinant GH may be a beneficial treatment.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/PeptidePathways/comments/1sb0nxo/peptide_research_for_crohns_disease/","title":"Peptide Research for Crohn's Disease","quote":"Tesamorelin elevates GH/IGF-1 for metabolic and reparative support.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":22871,"tokens_out":2681,"cost":0.03529125,"prev_hash":"genesis","hash":"039e581891576db3b1a168ecaeada741a244b88b4acdb97e129449ac1e47f3f1"}],"provenance":[{"ts":"2026-06-29T23:20:09.161Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Ibd\nSlug: tesamorelin-ibd\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"IBD (Crohn's / colitis)\",\"condition_key\":\"ibd-crohns-colitis\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have IBD (Crohn's / colitis)\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down if you have IBD (Crohn'","response":"{\n  \"slug\": \"tesamorelin-ibd\",\n  \"title\": \"Tesamorelin for IBD: Growth Hormone Axis Evidence in Crohn's and Colitis\",\n  \"body\": \"## What's breaking down if you have IBD (Crohn's / colitis)\\n\\nIBD involves ongoing damage to the intestinal lining where inflammation outpaces repair. Layers include barrier breakdown that lets contents leak, chronic cytokine-driven inflammation, impaired mucosal healing, and possible systemic effects like altered metabolism. GH and IGF-1 pathways support epithelial and mesenchymal cell growth plus immune cell balance in gut tissue. When these signals weaken or inflammation blocks them, repair lags and symptoms persist. Tesamorelin enters the discussion here because it raises endogenous GH via GHRH stimulation, which preclinical work links to trophic effects on gut cells.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about **IBD (Crohn's / colitis)** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nIf your IBD includes metabolic or visceral fat contributions that add systemic load, the GH axis route may intersect with tissue repair signals studied in growth factor research. Tesamorelin raises GH and IGF-1 levels in human trials focused on fat reduction. Those same signals show trophic effects on intestinal cells in separate GH studies. The logic chain stays at the repair layer: elevated GH could support epithelial survival and mucosal recovery if that pathway is relevant to your breakdown profile.\\n\\n## How these fit together\\n\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\\n\\nThis keeps the discussion on one degeneration layer per compound without overlap.\\n\\n## What the evidence actually shows\\n\\nHuman data on Tesamorelin its","tokens_in":22871,"tokens_out":2681,"cost":0,"prev":"genesis","hash":"a997429b28f93ef7d438c75e71e38a2c0c8779b9a3db68f73a5e17f05bfecdef"},{"ts":"2026-07-17T02:42:23.490Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-ibd","response":"23 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a997429b28f93ef7d438c75e71e38a2c0c8779b9a3db68f73a5e17f05bfecdef","hash":"5ef59e84c673591e84f3b997a4453ca57fe6a5fca4a24ca13aed6719fee05f59"}],"energy":{"passes":2,"tokens_in":22871,"tokens_out":2681,"tokens_total":25552,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5ef59e84c673591e84f3b997a4453ca57fe6a5fca4a24ca13aed6719fee05f59"},"posted_at":"2026-06-29T21:33:33.230Z","created_at":"2026-06-29T21:33:33.230Z","updated_at":"2026-07-17T02:42:23.490Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-ibd","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-ibd","json":"https://miscsubjects.com/api/articles/tesamorelin-ibd","bundle":"https://miscsubjects.com/api/articles/tesamorelin-ibd/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":4,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-ibd/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-ibd","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-ibd\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-ibd\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-ibd/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-ibd\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-ibd | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-ibd","json":"/api/articles/tesamorelin-ibd","markdown":"/api/articles/tesamorelin-ibd/bundle?format=markdown","skill":"/api/articles/tesamorelin-ibd/skill","topology":"/api/articles/tesamorelin-ibd/topology","versions":"/api/articles/tesamorelin-ibd/revisions","invocations":"/api/articles/tesamorelin-ibd/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-ibd","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"134ca73b860735312bd49b0d645eaf0de71dad8f6af3614ac49f245bc1eeb06e"}}}